Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy

• Status: Unknown status
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

to show that

1. patients improve and stabilize after 12 -24 week treatment with rivastigmine in memory function

2. use of rivastigmine has a positive effect on apathy in PSP patients

3. therapy with rivastigmine has a no positive benefit on speech and overall results of the MMST

4. changes in motor activity are associated with changes in language and overall results of the in MMST

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Tuebingen
• Treatments: Rivastigmine

Criteria

Inclusion Criteria:

• diagnosis of PSP

• willingness to participate in the study

• informed consent

• ability to speak

• no further CNS diseases

• written informed consent

• stable state of health

• ability to give informed consent, will checked by an independent physician

Exclusion Criteria:

• alcohol abuses

• acute psychosis

• pregnancy or lactation

• known previous drug reaction or hypersensitivity of rivastigmine or other carbamate derivatives

• liver failure

• known sick sinus syndrome or excitation disturbance

• known ulcus ventriculi or duodenal ulcer

• known asthma or COPD

• seizures

• renal failure